PROCTER & GAMBLE HEALTH | BAFNA PHARMA | PROCTER & GAMBLE HEALTH/ BAFNA PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | 18.4 | 187.6% | View Chart |
P/BV | x | 10.6 | 2.8 | 373.2% | View Chart |
Dividend Yield | % | 2.0 | 0.0 | - |
PROCTER & GAMBLE HEALTH BAFNA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
BAFNA PHARMA Mar-23 |
PROCTER & GAMBLE HEALTH/ BAFNA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 141 | 3,805.4% | |
Low | Rs | 3,883 | 79 | 4,945.9% | |
Sales per share (Unadj.) | Rs | 740.7 | 48.8 | 1,519.4% | |
Earnings per share (Unadj.) | Rs | 138.2 | 4.8 | 2,884.7% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 7.0 | 2,202.0% | |
Dividends per share (Unadj.) | Rs | 95.00 | 0 | - | |
Avg Dividend yield | % | 2.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 447.6 | 31.0 | 1,441.8% | |
Shares outstanding (eoy) | m | 16.60 | 23.66 | 70.2% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 2.3 | 277.3% | |
Avg P/E ratio | x | 33.5 | 22.9 | 146.1% | |
P/CF ratio (eoy) | x | 29.8 | 15.6 | 191.4% | |
Price / Book Value ratio | x | 10.3 | 3.5 | 292.3% | |
Dividend payout | % | 68.7 | 0 | - | |
Avg Mkt Cap | Rs m | 76,761 | 2,596 | 2,956.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 159 | 1,299.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 1,154 | 1,066.0% | |
Other income | Rs m | 184 | 33 | 561.9% | |
Total revenues | Rs m | 12,480 | 1,186 | 1,052.1% | |
Gross profit | Rs m | 3,247 | 157 | 2,065.9% | |
Depreciation | Rs m | 281 | 53 | 526.8% | |
Interest | Rs m | 8 | 20 | 37.8% | |
Profit before tax | Rs m | 3,142 | 116 | 2,704.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 3 | 30,478.4% | |
Profit after tax | Rs m | 2,295 | 113 | 2,023.9% | |
Gross profit margin | % | 26.4 | 13.6 | 193.8% | |
Effective tax rate | % | 27.0 | 2.4 | 1,125.6% | |
Net profit margin | % | 18.7 | 9.8 | 189.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 873 | 1,341.5% | |
Current liabilities | Rs m | 6,791 | 465 | 1,461.1% | |
Net working cap to sales | % | 40.0 | 35.4 | 113.1% | |
Current ratio | x | 1.7 | 1.9 | 91.8% | |
Inventory Days | Days | 263 | 2 | 15,327.2% | |
Debtors Days | Days | 343 | 1,302 | 26.4% | |
Net fixed assets | Rs m | 10,617 | 423 | 2,511.6% | |
Share capital | Rs m | 166 | 237 | 70.2% | |
"Free" reserves | Rs m | 7,265 | 498 | 1,458.8% | |
Net worth | Rs m | 7,431 | 735 | 1,011.6% | |
Long term debt | Rs m | 0 | 84 | 0.0% | |
Total assets | Rs m | 22,330 | 1,296 | 1,723.2% | |
Interest coverage | x | 409.1 | 6.7 | 6,105.5% | |
Debt to equity ratio | x | 0 | 0.1 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.9 | 61.9% | |
Return on assets | % | 10.3 | 10.3 | 99.9% | |
Return on equity | % | 30.9 | 15.4 | 200.1% | |
Return on capital | % | 42.4 | 16.7 | 254.2% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 13.1 | 7.9 | 166.2% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 1,605 | 91 | 1,771.8% | |
Fx inflow | Rs m | 1,465 | 885 | 165.5% | |
Fx outflow | Rs m | 1,605 | 91 | 1,771.8% | |
Net fx | Rs m | -140 | 794 | -17.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 50 | 4,764.8% | |
From Investments | Rs m | -215 | -75 | 286.9% | |
From Financial Activity | Rs m | -985 | 102 | -967.6% | |
Net Cashflow | Rs m | 1,160 | 76 | 1,519.3% |
Indian Promoters | % | 0.0 | 88.3 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 0.0 | - | |
FIIs | % | 6.2 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 11.7 | 411.8% | |
Shareholders | 56,778 | 7,539 | 753.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | BAFNA PHARM. | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | 1.00% | 0.45% |
1-Month | -1.15% | 9.49% | 2.55% |
1-Year | 0.73% | 3.22% | 56.14% |
3-Year CAGR | -8.76% | -13.67% | 15.22% |
5-Year CAGR | 4.97% | 57.71% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the BAFNA PHARM. share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of BAFNA PHARM. the stake stands at 88.3%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of BAFNA PHARM..
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
BAFNA PHARM. paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of BAFNA PHARM..
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.